CA3059660A1 - Phenoxyquinazoline compounds and their use in treating cancer - Google Patents

Phenoxyquinazoline compounds and their use in treating cancer Download PDF

Info

Publication number
CA3059660A1
CA3059660A1 CA3059660A CA3059660A CA3059660A1 CA 3059660 A1 CA3059660 A1 CA 3059660A1 CA 3059660 A CA3059660 A CA 3059660A CA 3059660 A CA3059660 A CA 3059660A CA 3059660 A1 CA3059660 A1 CA 3059660A1
Authority
CA
Canada
Prior art keywords
compound
formula
oxy
triazol
acetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3059660A
Other languages
English (en)
French (fr)
Inventor
Tudor GRECU
Jason Grant Kettle
Martin John Packer
Stuart Eric Pearson
James Michael Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CA3059660A1 publication Critical patent/CA3059660A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3059660A 2017-04-27 2018-04-26 Phenoxyquinazoline compounds and their use in treating cancer Pending CA3059660A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762490865P 2017-04-27 2017-04-27
US62/490,865 2017-04-27
PCT/EP2018/060800 WO2018197643A1 (en) 2017-04-27 2018-04-26 Phenoxyquinazoline compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
CA3059660A1 true CA3059660A1 (en) 2018-11-01

Family

ID=62165533

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3059660A Pending CA3059660A1 (en) 2017-04-27 2018-04-26 Phenoxyquinazoline compounds and their use in treating cancer

Country Status (7)

Country Link
US (1) US11053223B2 (https=)
EP (1) EP3615526B1 (https=)
JP (1) JP7117323B2 (https=)
CN (1) CN110546147B (https=)
CA (1) CA3059660A1 (https=)
ES (1) ES2887261T3 (https=)
WO (1) WO2018197643A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX389244B (es) 2017-04-27 2025-03-20 Astrazeneca Ab Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer
KR102674404B1 (ko) * 2018-04-20 2024-06-13 엘지전자 주식회사 저온 저장고의 냉각 시스템
KR102908062B1 (ko) * 2023-11-16 2026-01-05 (주)신테카바이오 헤테로아릴 유도체 화합물 및 이의 용도
CN118772070B (zh) * 2024-06-12 2025-12-16 天津济坤医药科技有限公司 一种喹唑啉衍生物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
US7709479B1 (en) * 1999-09-21 2010-05-04 Astrazeneca Quinazoline derivatives and their use as pharmaceuticals
EP1652847B1 (en) * 2001-04-27 2008-05-28 Kirin Pharma Kabushiki Kaisha Quinoline and quinazoline derivatives for the treatment of tumors
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
PT2213661E (pt) * 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
EP1802591B1 (en) * 2004-10-12 2012-01-11 AstraZeneca AB Quinazoline derivatives
CN1313449C (zh) * 2005-07-14 2007-05-02 沈阳中海生物技术开发有限公司 新的喹唑啉类衍生物、含有其的药物组合物以及它们的用途
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103254142B (zh) * 2013-04-26 2015-10-28 浙江工业大学 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用
CN104130200B (zh) * 2014-07-01 2016-04-20 中山大学 一种2-取代苯基-4-芳胺基喹唑啉衍生物及其制备方法和应用

Also Published As

Publication number Publication date
EP3615526A1 (en) 2020-03-04
US11053223B2 (en) 2021-07-06
ES2887261T3 (es) 2021-12-22
WO2018197643A1 (en) 2018-11-01
CN110546147A (zh) 2019-12-06
US20200223828A1 (en) 2020-07-16
EP3615526B1 (en) 2021-08-04
CN110546147B (zh) 2023-05-23
JP7117323B2 (ja) 2022-08-12
JP2020517676A (ja) 2020-06-18

Similar Documents

Publication Publication Date Title
US10829479B2 (en) C5-anilinoquinazoline compounds and their use in treating cancer
US9718806B2 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
EP3615526B1 (en) Phenoxyquinazoline compounds and their use in treating cancer
BR112019022229B1 (pt) Compostos de anilinoquinazolina c5, composição farmacêutica e uso dos compostos no tratamento do câncer
HK1216315B (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
NZ710850B2 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230426

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240918

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250404

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250404

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250505

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250505

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250505